AJANTPHARM3,540.00

Ajanta Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALKEMIPCALABTORNTPHARMABBOTINDIAANTHEMGLAXOMEDANTAGLENMARKMcap ₹44,374 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation135.4144.1173.1
+ Impairment Loss / (Reversal)-3.50.64.1
+ Finance Costs7.220.716.1
+ Interest Income-38.1-59.1-60.3
+ Fair Value (Gains) / Losses-13.712.587.4
+ Share-based Payments5.53.91.5
+ Unrealised FX (Gain) / Loss-9.4-10.3-58.1
+ Other Non-cash Items-0.3-0.3-0.3
Changes in Working Capital
+ Inventories-12.3-74.5-31.0
+ Trade Receivables — Current-178.980.5-590.8
+ Other Financial Assets — Current17.40.00.0
+ Other Financial Assets — Non-current1.70.00.0
+ Other Current Assets-40.925.3-158.8
+ Other Non-current Assets-1.00.00.0
+ Trade Payables — Current40.9-8.590.8
+ Other Financial Liabilities — Current19.50.00.0
+ Other Financial Liabilities — Non-current0.70.00.0
+ Other Current Liabilities36.6115.659.3
+ Provisions — Current1.240.5-22.4
+ Provisions — Non-current15.40.00.0
Cash from Operating Activities
Profit Before Tax (per I/S)1,113.91,189.21,377.71,493.3
+ Total Adjustments (incl. Working Capital)-16.7291.0-489.5
Cash from Operations (pre-tax)1,097.21,480.2888.2
+ Income Taxes Paid312.1323.0359.0
Cash from Operating Activities785.11,157.2529.2
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)152.4317.9365.2
+ Disp of Fixed Assets13.41.15.4
+ Purchase of Investments (Equity / Debt)2,079.82,761.22,660.0
+ Sale of Investments (Equity / Debt)2,257.42,663.52,549.1
+ Investment in Partnership Firms / LLPs0.06.33.3
+ Interest Received — Investing27.044.145.4
+ Other Inflows / (Outflows) — Investing-0.20.2-0.4
Cash from Investing Activities65.4-376.5-428.9
Cash from Financing Activities
+ Proceeds from Other Equity Instruments0.00.00.0
+ Buyback / Redemption of Own Shares389.2353.00.0
+ Proceeds from Borrowings0.11.1209.4
+ Payment of Lease Liabilities16.214.914.8
+ Interest Paid3.517.312.8
+ Dividends Paid642.2349.4349.7
Cash from Financing Activities-1,051.1-733.4-167.9
Net Changes in Cash (pre-FX)-200.647.3-67.7
+ Effect of FX Rate Changes on Cash0.3-1.7-4.2
Net Changes in Cash-200.345.6-71.9
Closing Cash129.5
Reference Items
EBITDA1,171.91,259.51,394.81,467.1
EBITDA Margin %27.8527.1025.5825.40
Free Cash Flow (CFO − Capex)632.7839.3164.0164.0
Free Cash Flow to Equity823.1360.6
Free Cash Flow per Basic Share50.4766.9613.0913.09
Price to Free Cash Flow270.52
Cash Flow to Net Income0.961.260.50
Cash Paid for Taxes312.1323.0359.0
Cash Paid for Interest3.517.312.8
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.